{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T05:39:58Z","timestamp":1740116398799,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diagn Pathol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Low-grade oncocytic tumor (LOT) of the kidney is an emerging entity among renal oncocytic tumors. While the histological features of LOT of the kidney are similar to those of renal oncocytoma, LOT immunohistochemically expresses keratin 7 (KRT7) but not KIT while renal oncocytoma expresses KIT. Molecular analyses of LOTs of the kidney using next generation sequencing revealed those tumors harbor mutations of mTOR-related genes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case presentation<\/jats:title>\n            <jats:p>An 80-year-old Japanese man with a history of clear cell renal cell carcinoma and prostatic cancer underwent resection of the tumor of the right kidney, 10\u00a0mm in diameter, which was monitored for six years. The tumor was histologically composed of oncocytic cells that expressed KRT7, vimentin, SDHA, SDHB and fumarate hydratase, but not KIT, GATA3 and alpha-methylacyl-CoA racemase. We diagnosed the tumor as LOT of the kidney. Whole-exome sequencing of the LOT revealed single nucleotide variants in the DNA-binding region of forkhead box I1 (<jats:italic>FOXI1<\/jats:italic>), the coil 1B domain of keratin 6\u00a0C (<jats:italic>KRT6C<\/jats:italic>) and the intracytoplasmic region of gap junction delta 2 (<jats:italic>GJD2<\/jats:italic>), which encodes connexin 36. However, there was no mutations in mTOR-related genes. No copy number alterations were detected in the tumor.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>We report three mutations in genes that have not been previously reported in LOT of the kidney. The genes are not related to the mTOR pathway. Therefore, LOT of the kidney might occur through several mechanisms and\/or include several types of renal oncocytic tumors.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13000-025-01616-3","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:42:06Z","timestamp":1740109326000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Whole exome sequencing identified mutations of forkhead box I 1 (FOXI1), keratin 6\u00a0C (KRT6C) and gap junction protein delta 2 (GJD2) in a low-grade oncocytic tumor of the kidney: a case report"],"prefix":"10.1186","volume":"20","author":[{"given":"Akinari","family":"Kakumoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Toki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rika","family":"Kasajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoji","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsunenori","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohei","family":"Miyagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuko","family":"Masunaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"key":"1616_CR1","unstructured":"Hartmann A, Gill AJ, He HY, Kryvenko ON, Ohashi R, Tretiakova MS. Oncocytoma of the kidney. In: the WHO classification of tumours editorial board, editors. Urinary and male genital tumours. WHO classification of the tumours, 5th ed. Lyon. 2022;50\u201352."},{"key":"1616_CR2","doi-asserted-by":"crossref","unstructured":"Trpkov K, Williamson SR, Gao Y, Martinek P, Cheng L, Sangoi AR et al. Low-grade oncocytic tumour of kidney (CD117-negative, cytokeratin 7-positive): a distinct entity? Histopathology. 2019;75:174\u2013\u200984.","DOI":"10.1111\/his.13865"},{"key":"1616_CR3","unstructured":"Harmann A, Gill AJ, He HY, Kryvenko ON, Ohashi R, Tretiakova MS. Chromophobe renal cell carcinoma. In: the WHO classification of tumours editorial board, editors. Urinary and male genital tumours. WHO classification of the tumours, 5th ed. Lyon. 2022;53-55."},{"key":"1616_CR4","first-page":"405","volume":"37","author":"M Mansoor","year":"2022","unstructured":"Mansoor M, Siadat F, Trpkov K. Low-grade oncocytic tumor (LOT)-a new renal entity ready for a prime time: an updated review. Histol Histopathol. 2022;37:405\u201313.","journal-title":"Histol Histopathol"},{"key":"1616_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.humpath.2021.04.013","volume":"114","author":"O Kravtsov","year":"2021","unstructured":"Kravtsov O, Gupta S, Cheville JC, Sukov WR, Rowsey R, Herrera-Hernandez LP, et al. Low-grade oncocytic tumor of kidney (CK7-positive, CD117-negative): incidence in a single institutional experience with clinicopathological and molecular characteristics. Hum Pathol. 2021;114:9\u201318.","journal-title":"Hum Pathol"},{"key":"1616_CR6","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/s41379-021-00906-7","volume":"35","author":"A Morini","year":"2022","unstructured":"Morini A, Drossart T, Timsit MO, Sibony M, Vasiliu V, Gimenez-Roqueplo AP, et al. Low-grade oncocytic renal tumor (LOT): mutations in mTOR pathway genes and low expression of FOXI 1. Mod Pathol. 2022;35:352\u201360.","journal-title":"Mod Pathol"},{"key":"1616_CR7","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41379-021-00969-6","volume":"35","author":"SK Mohanty","year":"2022","unstructured":"Mohanty SK, Satapathy A, Aggarwal A, Mishra SK, Sampat NY, Sharma S, et al. Oncocytic renal neoplasms with diffuse keratin 7 immunohistochemistry harbor frequent alterations in the mammalian target of rapamycin pathway. Mod Pathol. 2022;35:361\u201375.","journal-title":"Mod Pathol"},{"key":"1616_CR8","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41379-021-00896-6","volume":"35","author":"P Kapur","year":"2022","unstructured":"Kapur P, Gao M, Zhong H, Chintalapati S, Mitui M, Barnes SD, et al. Germline and sporadic mTOR pathway mutations in low-grade oncocytic tumor of the kidney. Mod Pathol. 2022;35:333\u201343.","journal-title":"Mod Pathol"},{"key":"1616_CR9","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00428-020-02927-0","volume":"478","author":"Q Guo","year":"2021","unstructured":"Guo Q, Liu N, Wang F, Guo Y, Yang B, Cao Z, et al. Characterization of a distinct low-grade oncocytic renal tumor (CD117-negative and cytokeratin 7-positive) based on a tertiary oncology center experience: the new evidence from China. Virchows Arch. 2021;478:449\u201358.","journal-title":"Virchows Arch"},{"key":"1616_CR10","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1136\/jclinpath-2021-207478","volume":"75","author":"M Akgul","year":"2022","unstructured":"Akgul M, Al-Obaidy KI, Cheng L, Idrees MT. Low-grade oncocytic tumours expands the spectrum of renal oncocytic tumours and deserves separate classification: a review of 23 cases from a single tertiary institute. J Clin Pathol. 2022;75:772\u20135.","journal-title":"J Clin Pathol"},{"key":"1616_CR11","unstructured":"Hartmann A, Gill AJ, He HY, Kryvenko ON, Ohashi R, Tretiakova MS. Other oncocytic tumours of the kidney. In: the WHO classification of tumours editorial board, editors. Urinary and male genital tumours. WHO classification of the tumours, 5th ed. Lyon. 2022;56\u201358."},{"key":"1616_CR12","doi-asserted-by":"crossref","unstructured":"Williamson SR, Hes O, Trpkov K, Aggarwal A, Satapathy A, Mishra S et al. Low-grade oncocytic tumour of the kidney is characterized by genetic alterations of TSC1, TSC2, MTOR or PIK3CA and consistent GATA3 positivity. Histopathology. 2023;82:296\u2013304.","DOI":"10.1111\/his.14816"},{"key":"1616_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/pore.2023.1610852","author":"T Chen","year":"2023","unstructured":"Chen T, Peng Y, Lei T, Wu C, Wang H, Shi Y. Low-grade oncocytic tumour (LOT) of the kidney is characterized by GATA3 positivity, FOXI1 negativity and mTOR pathway mutations. Pathol Oncol Res. 2023. https:\/\/doi.org\/10.3389\/pore.2023.1610852.","journal-title":"Pathol Oncol Res"},{"key":"1616_CR14","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00428-023-03673-9","volume":"483","author":"C Ricci","year":"2023","unstructured":"Ricci C, Ambrosi F, Franceschini T, Giunchi F, Grillini A, Franchini E, et al. Evaluation of an institutional series of low-grade oncocytic tumor (LOT) of the kidney and review of the mutational landscape of LOT. Virchows Arch. 2023;483:687\u201398.","journal-title":"Virchows Arch"},{"key":"1616_CR15","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1177\/10668969231178032","volume":"32","author":"SE Siegmund","year":"2024","unstructured":"Siegmund SE, Al-Obaidy KI, Tsai HK, Idrees MT, Akgul M, Acosta AM, et al. Concordance of MTOR pathway mutations and the diagnosis of renal low-grade oncocytic tumor (LOT). Int J Surg Pathol. 2024;32:316\u201330.","journal-title":"Int J Surg Pathol"},{"key":"1616_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0004471","author":"H Vidarsson","year":"2009","unstructured":"Vidarsson H, Westergren R, Heglind M, Blomqvist SR, Breton S, Enerb\u00e4ck S. The forkhead transcription factor Foxi 1 is a master regulator of vacuolar H+-ATPase proton pump subunits in the inner ear, kidney and epididymis. PLoS ONE. 2009. https:\/\/doi.org\/10.1371\/journal.pone.0004471.","journal-title":"PLoS ONE"},{"key":"1616_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-36921-z","author":"V Saxena","year":"2019","unstructured":"Saxena V, Fitch J, Ketz J, White P, Wetzel A, Chanley MA, et al. Whole transcriptome analysis of renal intercalated cells predicts lipopolysaccharide mediated inhibition of retinoid X receptor alpha function. Sci Rep. 2019. https:\/\/doi.org\/10.1038\/s41598-018-36921-z.","journal-title":"Sci Rep"},{"key":"1616_CR18","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.21873\/anticanres.13405","volume":"39","author":"A Molnar","year":"2019","unstructured":"Molnar A, Horvath CA, Czovek P, Szanto A, Kovacs G. FOXI 1 immunohistochemistry differentiates benign renal oncocytoma from malignant chromophobe renal cell carcinoma. Anticancer Res. 2019;39:2785\u201390.","journal-title":"Anticancer Res"},{"key":"1616_CR19","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00428-020-02900-x","volume":"478","author":"K Tong","year":"2021","unstructured":"Tong K, Hu Z. FOXI 1 expression in chromophobe renal cell carcinoma and renal oncocytoma: a study of the Cancer Genome Atlas transcriptome-based outlier mining and immunohistochemistry. Virchows Arch. 2021;478:647\u201358.","journal-title":"Virchows Arch"},{"key":"1616_CR20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.eururo.2020.03.003","volume":"78","author":"S Skala","year":"2020","unstructured":"Skala S, Wang X, Zhang Y, Mannan R, Wang L, Narayanan SP, et al. Next-generation RNA sequencing-based biomarker characterization of chromophobe renal cell carcinoma and related oncocytic neoplasms. Eur Urol. 2020;78:63\u201374.","journal-title":"Eur Urol"},{"key":"1616_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2023.1289388","author":"M Soleimani","year":"2023","unstructured":"Soleimani M. Not all kidney cysts are created equal: a distinct renal cystogenic mechanism in tuberous sclerosis complex (TSC). Front Physiol. 2023. https:\/\/doi.org\/10.3389\/fphys.2023.1289388.","journal-title":"Front Physiol"},{"key":"1616_CR22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1741-7007-9-16","volume":"9","author":"H Hermann","year":"2011","unstructured":"Hermann H, Strelkov SV. History and phylogeny of intermediate filaments: now in insects. BMC Biol. 2011;9:16. https:\/\/doi.org\/10.1186\/1741-7007-9-16.","journal-title":"BMC Biol"},{"key":"1616_CR23","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s13258-019-00889-5","volume":"42","author":"HB Hu","year":"2020","unstructured":"Hu HB, Yang XP, Zhou PX, Yang XA, Yin B. High expression of keratin 6\u00a0C is associated with poor prognosis and accelerates cancer proliferation and migration by modulating epithelial-mesenchymal transition in lung adenocarcinoma. Gene Genomics. 2020;42:179\u201388.","journal-title":"Gene Genomics"},{"key":"1616_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fphs.2022.839223","author":"T Kraujalis","year":"2022","unstructured":"Kraujalis T, Gudaitis L, Kraujaliene L, Snipas M, Palacois-Prado N, Verselis VK. The amino terminal domain and modulation of connexin36 gap junction channels by intracellular magnesium ions. Front Physiol. 2022. https:\/\/doi.org\/10.3389\/fphs.2022.839223","journal-title":"Front Physiol"},{"key":"1616_CR25","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00032.2017","author":"RT Alexander","year":"2017","unstructured":"Alexander RT, Dimke H. Effect of diuretics on renal tubular transport of calcium and magnesium. Am J Physiol Renal Physiol. 2017. https:\/\/doi.org\/10.1152\/ajprenal.00032.2017","journal-title":"Am J Physiol Renal Physiol"}],"container-title":["Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-025-01616-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13000-025-01616-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-025-01616-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:42:10Z","timestamp":1740109330000},"score":1,"resource":{"primary":{"URL":"https:\/\/diagnosticpathology.biomedcentral.com\/articles\/10.1186\/s13000-025-01616-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1616"],"URL":"https:\/\/doi.org\/10.1186\/s13000-025-01616-3","relation":{},"ISSN":["1746-1596"],"issn-type":[{"value":"1746-1596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,21]]},"assertion":[{"value":"21 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of his clinical details and analytic data. The consent has been uploaded to the electric medical chart of our hospital.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}